NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Paul J KennyAthina Markou

Abstract

Nicotine is considered an important component of tobacco responsible for the smoking habit in humans. Nicotine increases glutamate-mediated transmission throughout brain reward circuitries. This action of nicotine could potentially contribute to its intrinsic rewarding and reward-enhancing properties, which motivate consumption of the drug. Here we show that the competitive N-methyl-D-aspartate (NMDA) receptor antagonist LY235959 (0.5-2.5 mg per kg) abolished nicotine-enhanced brain reward function, reflected in blockade of the lowering of intracranial self-stimulation (ICSS) thresholds usually observed after experimenter-administered (0.25 mg per kg) or intravenously self-administered (0.03 mg per kg per infusion) nicotine injections. The highest LY235959 dose (5 mg per kg) tested reversed the hedonic valence of nicotine from positive to negative, reflected in nicotine-induced elevations of ICSS thresholds. LY235959 doses that reversed nicotine-induced lowering of ICSS thresholds also markedly decreased nicotine self-administration without altering responding for food reinforcement, whereas the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonist NBQX had no effects on nicotine intake. In addition, nic...Continue Reading

References

Aug 1, 1979·Experimental Eye Research·A Pellegrino de Iraldi, J P Corazza
Apr 1, 1992·Pharmacology, Biochemistry, and Behavior·D Huston-Lyons, C Kornetsky
Jan 1, 1991·Journal of Neural Transmission. General Section·D D SchoeppJ D Leander
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1995·Journal of Neurochemistry·H K PrinceA I Levey
May 1, 1996·Neuron·J A Dani, S Heinemann
Jun 12, 2001·Current Opinion in Neurobiology·S Cull-CandyM Farrant
Mar 7, 2002·Trends in Pharmacological Sciences·Bruno Buisson, Daniel Bertrand
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Evelyn K LambeGeorge K Aghajanian
Mar 5, 2003·Journal of Neurochemistry·Darlene H BrunzellMarina R Picciotto
Apr 30, 2003·Journal of Neurochemistry·Wen-Xue TangScott E Hemby
Nov 26, 2003·Drug and Alcohol Dependence·Jadwiga TurchanBarbara Przewlocka
Apr 14, 2004·The European Journal of Neuroscience·Emmanuel ValjentJocelyne Caboche
May 4, 2004·Trends in Pharmacological Sciences·Paul J Kenny, Athina Markou
May 18, 2004·Nature Neuroscience·Margaret E Rice, Stephanie J Cragg
Nov 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marisa RobertoGeorge Robert Siggins
Jan 22, 2005·Current Opinion in Pharmacology·Susan Jones, Antonello Bonci

❮ Previous
Next ❯

Citations

Apr 24, 2007·Neurotoxicity Research·Neil E Paterson, Athina Markou
Nov 13, 2012·Psychopharmacology·Amy M GancarzJerry B Richards
Sep 24, 2013·Neuropharmacology·Christie D Fowler, Paul J Kenny
May 13, 2009·Acta Pharmacologica Sinica·Zheng-xiong XiEliot L Gardner
Feb 4, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rubing Zhao-SheaAndrew R Tapper
Jun 10, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Manoranjan S D'SouzaAthina Markou
Aug 9, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bihua BieZhizhong Z Pan
Nov 27, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jonathan A HollanderPaul J Kenny
Oct 24, 2012·The Journal of Experimental Medicine·Shupeng LiFang Liu
Oct 2, 2012·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Dympna HarmeyPaul J Kenny
Jul 22, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Athina Markou
Jan 30, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michal KrawczykEric C Dumont
Jun 15, 2013·Pharmacology & Therapeutics·Paul Chu Sin Chung, Brigitte L Kieffer
Feb 19, 2014·Psychopharmacology·Joseph O'NeillEdythe D London
Jul 10, 2013·Neurochemical Research·Miklós PalotaiGyula Szabó
May 1, 2009·Expert Review of Clinical Pharmacology·Paul J Kenny
Nov 22, 2015·Brain Research Bulletin·Fawaz AlasmariYoussef Sari
Dec 4, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesco PistilloCecilia Gotti
Jun 7, 2012·Neuroscience and Biobehavioral Reviews·Lampros Perogamvros, Sophie Schwartz
Sep 8, 2010·Pharmacology, Biochemistry, and Behavior·Paul J Kenny
Nov 18, 2009·Pharmacology & Therapeutics·Bianca Jupp, Andrew J Lawrence
Aug 12, 2009·Neuroscience and Biobehavioral Reviews·Peter DomeZoltan Rihmer
Nov 26, 2015·Frontiers in Neuroscience·Manoranjan S D'Souza
Jul 25, 2012·Alcoholism, Clinical and Experimental Research·Yu-Wei ChenSarah F Leibowitz
Oct 29, 2009·Alcoholism, Clinical and Experimental Research·Eric W FishC J Malanga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.